Advertisement

AAPS PharmSciTech

, 20:330 | Cite as

Development and Assessment of Lipidic Nanoemulsions Containing Sodium Hyaluronate and Indomethacin

  • Ibtissem GuermechEmail author
  • Mohamed Ali Lassoued
  • Amal Abdelhamid
  • Souad Sfar
Research Article
  • 72 Downloads

Abstract

The present work attempts to develop and optimize the formula of a lipidic nanoemulsion (NE) containing sodium hyaluronate (HNa) and indomethacin (Ind) as HNa–Ind for enhanced transdermal antiarthritic activity. NEs were prepared by the spontaneous emulsification method and characterized by Fourier-transform infrared (FTIR) spectroscopy. The composition of the optimal formulation was statistically optimized using Box–Behnken experimental design method with three independent factors and was characterized for particle size, polydispersity index, and percent transmittance. The selected formula was tested for its in vitro antioxidant activity and in vivo anti-inflammatory activity. The optimized HNa–Ind NE formula was characterized and displayed a particle size of 12.87 ± 0.032 nm, polydispersity index of 0.606 ± 0.082, and 99.4 ± 0.1 percentage of transmittance. FTIR showed no interaction between HNa and Ind as a physical mixture. In addition, the optimized HNa–Ind NE was able to preserve the antioxidant ability of the two drugs, as evidenced through a 2,2-diphenyl-1-picrylhydrazyl (DPPH) inhibition assay used to assess free radical scavenging ability. The cell viability was increased while the free radical scavenging activity was decreased (94.28% inhibition at higher concentrations compared with vitamin C as a reference with an inhibition of 100%). Moreover, the pharmacological anti-inflammatory potential of the optimized HNa–Ind NE formulation was assessed using an in vivo model. Compared with reference drugs (ibuprofen gel 5%), the remarkable activity of the optimized formulation was established using xylene-induced ear edema in mice model, in which the inflamed region reduced by 92.5% upon treatment. The optimized HNa–Ind NE formulation showed considerably higher skin permeation and drug deposition capability compared with the HNa–Ind solution. HNa–Ind NE was demonstrated to be a successful carrier with enhanced antioxidant and anti-inflammatory potential while showing better skin penetration, thus being a promising vehicle for transdermal drug delivery.

KEY WORDS

sodium hyaluronate indomethacin nanoemulsion Box–Behnken design antioxidant activity anti-inflammatory activity 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Chevalier X. Le cartilage normal: Physiopathégnie de l’arthrose. La Presse médicale 27. EMC - Appareil locomoteur. 1998;75–80.Google Scholar
  2. 2.
    Liao YH, Jones SA, Forbes B, Martin GP, Brown MB. Hyaluronan: pharmaceutical characterization and drug delivery. Drug Delivery. 2005;12:327–42.  https://doi.org/10.1080/10717540590952555.CrossRefPubMedGoogle Scholar
  3. 3.
    Hochberg MC. Role of intra-articular hyaluronic acid preparations in medical management of osteoarthritis of the knee. Semin Arthritis Rheum. 2000;30:2–10.  https://doi.org/10.1053/sarh.2000.0245.CrossRefPubMedGoogle Scholar
  4. 4.
    Altman RD. Intra-articular sodium hyaluronate in osteoarthritis of the knee. Semin Arthritis Rheum. 2000;30:11–8.  https://doi.org/10.1053/sarh.2000.0248.CrossRefPubMedGoogle Scholar
  5. 5.
    Dougados M. Sodium hyaluronate therapy in osteoarthritis: arguments for a potential beneficial structural effect. Semin Arthritis Rheum. 2000;30:19–25.  https://doi.org/10.1053/sarh.2000.0246.CrossRefPubMedGoogle Scholar
  6. 6.
    Guidolin DD, Ronchetti IP, Lini E, Guerra D, Frizziero L. Morphological analysis of articular cartilage biopsies from a randomized, clinical study comparing the effects of 500-730 kDa sodium hyaluronate (Hyalgan(R)) and methylprednisolone acetate on primary osteoarthritis of the knee. Osteoarthr Cartil. 2001;9:371–81.  https://doi.org/10.1053/joca.2000.0398.CrossRefPubMedGoogle Scholar
  7. 7.
    Maheu E, Ayral X, Dougados M. A hyaluronan preparation (500–730 kDa) in the treatment of osteoarthritis: a review of clinical trials with Hyalgan. Int J Clin Pract. 2002;56:804–13.PubMedGoogle Scholar
  8. 8.
    Barrett JP, Siviero P. Retrospective study of outcomes in Hyalgan(R)-treated patients with osteoarthritis of the knee. Clin Drug Invest. 2002;22:87–97.  https://doi.org/10.2165/00044011-200222020-00003.CrossRefGoogle Scholar
  9. 9.
    Miltner O, Schneider U, Siebert CH, Niedhart C, Niethard FU. Efficacy of intraarticular hyaluronic acid in patients with osteoarthritis—a prospective clinical trial. Osteoarthritis Cartilage. 2002;10:680–6.  https://doi.org/10.1053/joca.2002.0815.CrossRefPubMedGoogle Scholar
  10. 10.
    Tascioglu F, Öner C. Efficacy of intra-articular sodium hyaluronate in the treatment of knee osteoarthritis. Clin Rheumatol. 2003;22:112–7.  https://doi.org/10.1007/s10067-002-0690-1.CrossRefGoogle Scholar
  11. 11.
    Uthman I, Raynauld JP, Haraoui B. Intra-articular therapy in osteoarthritis. Postgrad Med J. 2003;79:449–53.  https://doi.org/10.1136/pmj.79.934.449.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kelly MA, Goldberg VM, Healy WL, Pagnano MW, Hamburger MI. Osteoarthritis and beyond: a consensus on the past, present, and future of hyaluronans in orthopedics. Orthopedics. 2003;26:1064–79.PubMedGoogle Scholar
  13. 13.
    Hamburger MI, Lakhanpal S, Mooar PA, Oster D. Intra-articular hyaluronans: a review of product-specific safety profiles. Semin Arthritis Rheum. 2003;32:296–309.  https://doi.org/10.1053/sarh.2002.50008.CrossRefPubMedGoogle Scholar
  14. 14.
    Kirwan J. Is there a place for intra-articular hyaluronate in osteoarthritis of the knee? Knee. 2001;8:93–101.  https://doi.org/10.1016/S0968-0160(01)00075-8.CrossRefPubMedGoogle Scholar
  15. 15.
    Ayhan E, Kesmezacar H, Akgun I. Intraarticular injections (corticosteroid, hyaluronic acid, platelet rich plasma) for the knee osteoarthritis. World J Orthop. 2014;5(3):351–61.  https://doi.org/10.5312/wjo.v5.i3.351.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Garg HG, Hales CA. Chemistry and biology of hyaluronan. Elsevier Science, ISBN: 978-0-08-044382-9. Dermatology. 2004:251–8.Google Scholar
  17. 17.
    Necas J, Bartosikova L, Brauner P, Kolar J. Hyaluronic acid (hyaluronan): a review. Vet Med. 2008;53:397–411.  https://doi.org/10.17221/1930-vetmed.CrossRefGoogle Scholar
  18. 18.
    Falcone SJ, Palmeri D, Berg RA. Biomedical applications of hyaluronic acid. ACS Symp Ser. 2006:155–74.  https://doi.org/10.1021/bk-2006-0934.ch008.Google Scholar
  19. 19.
    Albert C, Brocq O, Gerard D, Roux C, Euller-Ziegler L. Septic knee arthritis after intra-articular hyaluronate injection: Two case reports. Joint Bone Spine. 2006;73:205–7.  https://doi.org/10.1016/j.jbspin.2005.03.005.CrossRefPubMedGoogle Scholar
  20. 20.
    Bernardeau C, Bucki B, Lioté F. Acute arthritis after intra-articular hyaluronate injection: onset of effusions without crystal. Ann Rheum Dis. 2001;60:518–20.  https://doi.org/10.1136/ard.60.5.518.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Roos J, Epaulard O, Juvin R, Chen C, Pavese P, Brion JP. Acute pseudoseptic arthritis after intraarticular sodium hyaluronan. Joint Bone Spine. 2004;71:352–4.  https://doi.org/10.1016/j.jbspin.2003.09.001.CrossRefPubMedGoogle Scholar
  22. 22.
    Abiteboul M, Mazières B, Causse B, Moatti N, Arlet J. Septic arthritis of the knee due to Neisseria mucosa. Clin Rheumatol. 1985;4:83–5.  https://doi.org/10.1007/BF02032323.CrossRefPubMedGoogle Scholar
  23. 23.
    Van Linthoudt D, Modde H, Ott H. Neisseria mucosa septic arthritis. Br J Rheumatol. 1987;26:314.  https://doi.org/10.1093/rheumatology/26.4.314.CrossRefPubMedGoogle Scholar
  24. 24.
    Mikulak SA, Vangsness CT, Nimni ME. Transdermal delivery and accumulation of indomethacin in subcutaneous tissues in rats. J Pharm Pharmacol. 1998;50:153–8.  https://doi.org/10.1111/j.2042-7158.1998.tb06170.x.CrossRefPubMedGoogle Scholar
  25. 25.
    Kathiresan K, Kiran K, Vijin P, Sreenu VS, Manavalan R. Formulation and development of indomethacin sustained release tablets. Int J PharmTech Res. 2010;2:794–7.Google Scholar
  26. 26.
    Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S. Celecoxib nanoemulsion: skin permeation mechanism and bioavailability assessment. J Drug Target. 2008;16:733–40.  https://doi.org/10.1080/10611860802473402.CrossRefPubMedGoogle Scholar
  27. 27.
    Baboota S, Shakeel F, Kohli K. Formulation and evaluation of once a day transdermal gels of diclofenac diethylamine. Methods Find Exp Clin Pharmacol. 2006;28:109–14.  https://doi.org/10.1358/mf.2006.28.2.977842.CrossRefPubMedGoogle Scholar
  28. 28.
    Wu H, Ramachandran C, Weiner ND, Roessler BJ. Topical transport of hydrophilic compounds using water-in-oil nanoemulsions. Int J Pharm. 2001;220:63–75.  https://doi.org/10.1016/S0378-5173(01)00671-8.CrossRefPubMedGoogle Scholar
  29. 29.
    Mou D, Chen H, Du D, Mao C, Wan J, Xu H, et al. Hydrogel-thickened nanoemulsion system for topical delivery of lipophilic drugs. Int J Pharm. 2008;353:270–6.  https://doi.org/10.1016/j.ijpharm.2007.11.051.CrossRefPubMedGoogle Scholar
  30. 30.
    Gupta A, Eral HB, Hatton TA, Doyle PS. Nanoemulsions: formation, properties and applications. Soft Matter. 2016;12:2825–41.  https://doi.org/10.1039/c5sm02958a.CrossRefGoogle Scholar
  31. 31.
    El-Maghraby GM. Transdermal delivery of hydrocortisone from eucalyptus oil microemulsion: effects of cosurfactants. Int J Pharm. 2008;355:285–92.  https://doi.org/10.1016/j.ijpharm.2007.12.022.CrossRefPubMedGoogle Scholar
  32. 32.
    Shakeel F, Ramadan W, Ahmed MA. Investigation of true nanoemulsions for transdermal potential of indomethacin: characterization, rheological characteristics, and ex vivo skin permeation studies. J Drug Target. 2009;17:435–41.  https://doi.org/10.1080/10611860902963021.CrossRefPubMedGoogle Scholar
  33. 33.
    Nasr M. Development of an optimized hyaluronic acid-based lipidic nanoemulsion co-encapsulating two polyphenols for nose to brain delivery. Drug Delivery. 2016;23:1444–52.  https://doi.org/10.3109/10717544.2015.1092619.CrossRefPubMedGoogle Scholar
  34. 34.
    Shetty PK, Venuvanka V, Jagani HV, Chethan GH, Ligade VS, Musmade PB, et al. Development and evaluation of sunscreen creams containing morin-encapsulated nanoparticles for enhanced UV radiation protection and antioxidant activity. Int J Nanomedicine. 2015;10:6477–91.  https://doi.org/10.2147/IJN.S90964.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Gilli R, Kacuráková M, Mathlouthi M, Navarini L, Paoletti S. FTIR studies of sodium hyaluronate and its oligomers in the amorphous solid phase and in aqueous solution. Carbohydr Res. 1994;263:315–26.  https://doi.org/10.1016/0008-6215(94)00147-2.CrossRefPubMedGoogle Scholar
  36. 36.
    Gradzielski M, Langevin D, Farago B. Experimental investigation of the structure of nonionic microemulsions and their relation to the bending elasticity of the amphiphilic film. Phys Rev E. 1996;53:3900–19.  https://doi.org/10.1103/PhysRevE.53.3900.CrossRefGoogle Scholar
  37. 37.
    El-Leithy ES, Ibrahim HK, Sorour RM. In vitro and in vivo evaluation of indomethacin nanoemulsion as a transdermal delivery system. Drug Delivery. 2013;22:1010–7.  https://doi.org/10.3109/10717544.2013.844742.CrossRefPubMedGoogle Scholar
  38. 38.
    Baboota S, Al-Azaki A, Kohli K, Ali J, Dixit N, Shakeel F. Development and evaluation of a microemulsion formulation for transdermal delivery of terbinafine. PDA J Pharm Sci Technol. 2007;61:276–85.PubMedGoogle Scholar
  39. 39.
    Shakeel F, Baboota S, Ahuja A, Ali J, Aqil M, Shafiq S. Nanoemulsions as vehicles for transdermal delivery of aceclofenac. AAPS PharmSciTech. 2007;8:191–9.  https://doi.org/10.1208/pt0804104.CrossRefPubMedCentralGoogle Scholar
  40. 40.
    Shakeel F, Baboota S, Ahuja A, All J, Shafiq S. Skin permeation mechanism of aceclofenac using novel nanoemulsion formulation. Pharmazie. 2008;63:580–4.PubMedGoogle Scholar
  41. 41.
    Guermech I, Jouan Y, Hay E, Marty C, Cohen-Solal M, Sfar S. Evaluation of intra-articular delivery of the internal phase of a sodium hyaluronate and indomethacin-based nanoemulsion in primary articular chondrocytes. J Clin Exp Pharmacol. 2019;9:261.  https://doi.org/10.4172/2161-1459.1000261.CrossRefGoogle Scholar
  42. 42.
    Mishra RK, Soni GC, Mishra RP. A review article: on nanoemulsion. World J Pharm Pharm Sci. 2014;3:258–74.Google Scholar
  43. 43.
    Moghimipour E, Salimi A, Karami M, Isazadeh S. Preparation and characterization of dexamethasone microemulsion based on pseudoternary phase diagram. Jundishapur J Nat Pharm Prod. 2013;8:105–12.  https://doi.org/10.17795/jjnpp-9373.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Bali V, Ali M, Ali J. Study of surfactant combinations and development of a novel nanoemulsion for minimising variations in bioavailability of ezetimibe. Colloids Surf B Biointerfaces. 2010;76:410–20.  https://doi.org/10.1016/j.colsurfb.2009.11.021.CrossRefPubMedGoogle Scholar
  45. 45.
    Caddeo C, Manconi M, Fadda AM, Lai F, Lampis S, Diez-Sales O, et al. Nanocarriers for antioxidant resveratrol: formulation approach, vesicle self-assembly and stability evaluation. Colloids Surf. B. 2013;111:327–32.  https://doi.org/10.1016/j.colsurfb.2013.06.016.CrossRefGoogle Scholar
  46. 46.
    Tavano L, Muzzalupo R, Picci N, de Cindio B. Co-encapsulation of lipophilic antioxidants into niosomal carriers: percutaneous permeation studies for cosmeceutical applications. Colloids Surf. B. 2014;114:144–9.  https://doi.org/10.1016/j.colsurfb.2013.09.055.CrossRefGoogle Scholar
  47. 47.
    Guidelines for Psychologists Working with Animals. The British Psychological Society. 2012.  https://doi.org/10.1080/713932742
  48. 48.
    Kou J, Ni Y, Li N, Wang J, Liu L, Jiang ZH. Analgesic and anti-inflammatory activities of total extract and individual fractions of Chinese medicinal ants Polyrhachis lamellidens. Biol Pharm Bull. 2005;28:176–80.  https://doi.org/10.1248/bpb.28.176.CrossRefPubMedGoogle Scholar
  49. 49.
    Lu HM, Liang YZ, Yi LZ, Wu XJ. Anti-inflammatory effect of Houttuynia cordata injection. J Ethnopharmacol. 2006;104:245–9.  https://doi.org/10.1016/j.jep.2005.09.012.CrossRefPubMedGoogle Scholar
  50. 50.
    Avadhani KS, Manikkath J, Tiwari M, Chandrasekhar M, Godavarthi A, Vidya SM, et al. Skin delivery of epigallocatechin-3-gallate (EGCG) and hyaluronic acid loaded nano-transfersomes for antioxidant and anti-aging effects in UV radiation induced skin damage. Drug Delivery. 2017;24:61–74.  https://doi.org/10.1080/10717544.2016.1228718.CrossRefPubMedGoogle Scholar
  51. 51.
    Badawi AA, El-Laithy HM, El Qidra RK, El Mofty H, El Dally M. Chitosan based nanocarriers for indomethacin ocular delivery. Arch Pharm Res. 2008;31:1040–9.  https://doi.org/10.1007/s12272-001-1266-6.CrossRefPubMedGoogle Scholar
  52. 52.
    Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000;45:89–121.  https://doi.org/10.1016/S0169-409X(00)00103-4.CrossRefPubMedGoogle Scholar
  53. 53.
    Craig DQM, Barker SA, Banning D, Booth SW. An investigation into the mechanisms of self-emulsification using particle size analysis and low frequency dielectric spectroscopy. Int J Pharm. 1995;114:103–10.  https://doi.org/10.1016/0378-5173(94)00222-Q.CrossRefGoogle Scholar
  54. 54.
    Lee RW, Shenoy DB, Sheel R. Handbook of non-invasive drug delivery systems, 1st edn, In: Vitthal S. Kulkarni, USA, 2010. Non-Invasive and minimally-invasive drug delivery systems for pharmaceutical and personal care products. Personal Care & Cosmetic Technology; 2010. p. 37–58.Google Scholar
  55. 55.
    Jona JA, Dittert LW, Crooks PA, Milosovich SM, Hussain AA. Design of novel prodrugs for the enhancement of the transdermal penetration of indomethacin. Int J Pharm. 1995;123:127–36.  https://doi.org/10.1016/0378-5173(95)00061-m.CrossRefGoogle Scholar
  56. 56.
    Sen R, Swaminathan T. Response surface modeling and optimization to elucidate and analyze the effects of inoculum age and size on surfactin production. Biochem Eng J. 2004;21:141–8.  https://doi.org/10.1016/j.bej.2004.06.006.CrossRefGoogle Scholar
  57. 57.
    Liu HL, Lan YW, Cheng YC. Optimal production of sulphuric acid by Thiobacillus thiooxidans using response surface methodology. Process Biochem. 2004;39:1953–61.  https://doi.org/10.1016/j.procbio.2003.09.018.CrossRefGoogle Scholar
  58. 58.
    Adinarayana K, Ellaiah P. Response surface optimization of the critical medium components for the production of alkaline protease by a newly isolated Bacillus sp. J Pharm Pharm Sci. 2002;5:272–8.PubMedGoogle Scholar
  59. 59.
    Yetilmezsoy K, Demirel S, Vanderbei RJ. Response surface modeling of Pb (II) removal from aqueous solution by Pistacia vera L.: Box–Behnken experimental design. J Hazard Mater. 2009;171:551–62.  https://doi.org/10.1016/j.jhazmat.2009.06.035.CrossRefPubMedGoogle Scholar
  60. 60.
    Chen H, Chang X, Du D, Li J, Xu H, Yang X. Microemulsion-based hydrogel formulation of ibuprofen for topical delivery. Int J Pharm. 2006;315:52–8.  https://doi.org/10.1016/j.ijpharm.2006.02.015.CrossRefPubMedGoogle Scholar
  61. 61.
    Misra S, Ghatak S, Zoltan-Jones A, Toole BP. Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem. 2002;278:25285–8.  https://doi.org/10.1074/jbc.c300173200.CrossRefGoogle Scholar
  62. 62.
    Termeer CC, Hennies J, Voith U, Ahrens T, Weiss JM, Prehm P, et al. Oligosaccharides of hyaluronan are potent activators of dendritic cells. J Immunol. 2000;165:1863–70.  https://doi.org/10.4049/jimmunol.165.4.1863.CrossRefPubMedGoogle Scholar
  63. 63.
    Trabucchi E, Pallotta S, Morini M, Corsi F, Franceschini R, Casiraghi A, et al. Low molecular weight hyaluronic acid prevents oxygen free radical damage to granulation tissue during wound healing. Int J Tissue React. 2002;24:65–71.PubMedGoogle Scholar
  64. 64.
    Donsì F, Sessa M, Mediouni H, Mgaidi A, Ferrari G. Encapsulation of bioactive compounds in nanoemulsion-based delivery systems. Procedia Food Sci. 2011;1:1666–71.  https://doi.org/10.1016/j.profoo.2011.09.246.CrossRefGoogle Scholar
  65. 65.
    Jacobs RS, Culver P, Langdon R, O’Brien T, White S. Some pharmacological observations on marine natural products. Tetrahedron. 1985;41:981–4.  https://doi.org/10.1016/S0040-4020(01)96465-8.CrossRefGoogle Scholar
  66. 66.
    Goldman L, Igelman JM, Kitzmiller K. Investigative studies with DMSO in dermatology. Ann N Y Acad Sci. 1967;141:428–36.  https://doi.org/10.1111/j.1749-6632.1967.tb34907.x.CrossRefGoogle Scholar
  67. 67.
    Duimel-Peeters IGP, Houwing RH, Teunissen CP, Berger MPF, Snoeckx LHEH, Halfens RJG. A systematic review of the efficacy of topical skin application of dimethyl sulfoxide on wound healing and as an anti-inflammatory drug. Wounds. 2003;15:361–70.Google Scholar
  68. 68.
    Ghosh P, Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum. 2002;32:10–37.  https://doi.org/10.1053/sarh.2002.33720.CrossRefPubMedGoogle Scholar
  69. 69.
    Zhu Y, Granick S. Biolubrication: Hyaluronic acid and the influence on its interfacial viscosity of an antiinflammatory drug. Macromolecules. 2003;36:973–6.  https://doi.org/10.1021/ma025988r.CrossRefGoogle Scholar
  70. 70.
    Nandi I, Bari M, Joshi H. Study of isopropyl myristate microemulsion systems containing cyclodextrins to improve the solubility of 2 model hydrophobic drugs. AAPS PharmSciTech. 2003;4:71–9.  https://doi.org/10.1208/pt040110.CrossRefPubMedCentralGoogle Scholar
  71. 71.
    Walters KA. Penetration enhancers and their use in transdermal therapeutic systems. In: Hadgraft J, Guy RH, editors. Transdermal drug delivery, developmental issues and research initiatives. New York: Marcel Dekker; 1989. 197Y246.Google Scholar
  72. 72.
    Artusi M, Nicoli S, Colombo P, Bettini R, Sacchi A, Santi P. Effect of chemical enhancers and iontophoresis on thiocolchicoside permeation across rabbit and human skin in vitro. J Pharm Sci. 2004;93:2431–8.  https://doi.org/10.1002/jps.20152.CrossRefPubMedGoogle Scholar
  73. 73.
    Barry BW. Mode of action of penetration enhancers in human skin. J Control Release. 1987;6:85–97.  https://doi.org/10.1016/0168-3659(87)90066-6.CrossRefGoogle Scholar
  74. 74.
    Vega E, Egea MA, Garduño-Ramírez ML, García ML, Sánchez E, Espina M, et al. Flurbiprofen PLGA-PEG nanospheres: role of hydroxy-beta-cyclodextrin on ex vivo human skin permeation and in vivo topical anti-inflammatory efficacy. Colloids Surf. B. 2013;110:339–46.  https://doi.org/10.1016/j.colsurfb.2013.04.045.CrossRefGoogle Scholar
  75. 75.
    Baroli B, López-Quintela MA, Delgado-Charro MB, Fadda AM, Blanco-Méndez J. Microemulsions for topical delivery of 8-methoxsalen. J Control Release. 2000;69:209–18.  https://doi.org/10.1016/S0168-3659(00)00309-6.CrossRefPubMedGoogle Scholar
  76. 76.
    Delgado-Charro MB, Iglesias-Vilas G, Blanco-Méndez J, López-Quintela MA, Marty JP, Guy RH. Delivery of a hydrophilic solute through the skin from novel microemulsion systems. Eur J Pharm Biopharm. 1997;43:37–42.  https://doi.org/10.1016/S0939-6411(96)00016-1.CrossRefGoogle Scholar
  77. 77.
    Zhu W, Yu A, Wang W, Dong R, Wu J, Zhai G. Formulation design of microemulsion for dermal delivery of penciclovir. Int J Pharm. 2008;360:184–90.  https://doi.org/10.1016/j.ijpharm.2008.04.008.CrossRefPubMedGoogle Scholar
  78. 78.
    Rhee YS, Choi JG, Park ES, Chi SC. Transdermal delivery of ketoprofen using microemulsions. Int J Pharm. 2001;228:161–70.  https://doi.org/10.1016/S0378-5173(01)00827-4.CrossRefPubMedGoogle Scholar
  79. 79.
    Chang XL, Chen HB, Zhao XZ, Gao ZH, Xu HB, Yang XL. High-performance liquid chromatography determination of triptolide in vitro permeation studies. Anal Chim Acta. 2005;534:215–21.  https://doi.org/10.1016/j.jns.2004.11.036.CrossRefGoogle Scholar
  80. 80.
    Changez M, Chander J, Dinda AK. Transdermal permeation of tetracaine hydrochloride by lecithin microemulsion: in vivo. Colloids Surf. B. 2006;48:58–66.  https://doi.org/10.1016/j.colsurfb.2006.01.007.CrossRefGoogle Scholar
  81. 81.
    Mei Z, Chen H, Weng T, Yang Y, Yang X. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur J Pharm Biopharm. 2003;56:189–96.  https://doi.org/10.1016/S0939-6411(03)00067-5.CrossRefPubMedGoogle Scholar
  82. 82.
    Mayka MF. Developpement Des Formes Transdermiques, Thèse d’exercice en Pharmacie, Université Toulouse III - Paul Sabatier; 2014.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  • Ibtissem Guermech
    • 1
    Email author
  • Mohamed Ali Lassoued
    • 1
  • Amal Abdelhamid
    • 1
  • Souad Sfar
    • 1
  1. 1.Laboratory of Chemical, Galenic and Pharmacological Development of Drugs (LR12ES09), Faculty of Pharmacy of MonastirUniversity of MonastirMonastirTunisia

Personalised recommendations